Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Eugene Krustev, Ann E. Clarke & Megan R.W. Barber. (2023) B cell depletion and inhibition in systemic lupus erythematosus. Expert Review of Clinical Immunology 19:1, pages 55-70.
Read now
Read now
Fan Shi, Ran Xue, Xuexiao Zhou, Pei Shen, Shengzhi Wang & Yun Yang. (2021) Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease. Immunopharmacology and Immunotoxicology 43:6, pages 666-673.
Read now
Read now
Articles from other publishers (23)
Pawlak-Buś Katarzyna, Schmidt Wiktor, Dudziec Ewa & Leszczyński Piotr. (2023) Current treatment of systemic lupus erythematosus: a clinician's perspective. Rheumatology International 43:8, pages 1395-1407.
Crossref
Crossref
Mohamed W. Attwa, Aishah M. Alsibaee, Haya I. Aljohar, Ali S. Abdelhameed & Adnan A. Kadi. (2023) Development of a Fast and Sensitive UPLC–MS/MS Analytical Methodology for Fenebrutinib Estimation in Human Liver Microsomes: In Vitro and In Silico Metabolic Stability Evaluation. Separations 10:5, pages 302.
Crossref
Crossref
Franz Felix Konen, Nora Möhn, Torsten Witte, Matthias Schefzyk, Miriam Wiestler, Svjetlana Lovric, Karsten Hufendiek, Philipp Schwenkenbecher, Kurt-Wolfram Sühs, Manuel A. Friese, Luisa Klotz, Refik Pul, Marc Pawlitzki, David Hagin, Christoph Kleinschnitz, Sven G. Meuth & Thomas Skripuletz. (2023) Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. Autoimmunity Reviews 22:5, pages 103312.
Crossref
Crossref
Laura Connelly‐Smith, Caroline R. Alquist, Nicole A. Aqui, Jan C. Hofmann, Reinhard Klingel, Oluwatoyosi A. Onwuemene, Christopher J. Patriquin, Huy P. Pham, Amber P. Sanchez, Jennifer Schneiderman, Volker Witt, Nicole D. Zantek & Nancy M. Dunbar. (2023) Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. Journal of Clinical Apheresis 38:2, pages 77-278.
Crossref
Crossref
E. M. Kalashnikova, R. K. Raupov, N. A. Lyubimova, E. M. Kuchinskaya, V. V. Masalova, E. A. Isupova, E. V. Gaidar, M. F. Dubko, L. S. Snegireva, L. S. Sorokina, T. L. Kornishina, M. A. Kaneva, I. A. Chikova, T. S. Likhacheva, O. L. Kolobova, O. V. Kalashnikova, V. G. Chasnyk & M. M. Kostik. (2023) The experience of rituximab therapy in patients with juvenile systemic lupus erythematosus: the preliminary results of two-center cohort study. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 68:1, pages 74-84.
Crossref
Crossref
Sankha Bhattacharya. (2023) An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer. Critical Reviews in Oncology/Hematology 183, pages 103916.
Crossref
Crossref
Andrew Courtwright, Carl Atkinson & Andres Pelaez. (2023) The Highly Sensitized Recipient. Clinics in Chest Medicine 44:1, pages 85-93.
Crossref
Crossref
Sophia Ly, Dmitry Nedosekin & Henry K. Wong. (2023) Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin. American Journal of Clinical Dermatology 24:2, pages 247-273.
Crossref
Crossref
Ana Lorenzo-Vizcaya & David Alan Isenberg. (2023) Clinical trials in systemic lupus erythematosus: the dilemma—Why have phase III trials failed to confirm the promising results of phase II trials?. Annals of the Rheumatic Diseases 82:2, pages 169-174.
Crossref
Crossref
Nikita Kedia, Vincent Theillac, Manuel Paez-Escamilla, Chad Indermill, Denise S. Gallagher, Raphaël Adam, Anne Lise Qu-Knafo, Fatima Amari, Caroline Bottin, Géraldine Chotard, Violaine Caillaux, Maté Strého, Neila Sedira, Emmanuel Héron, Pierre-André Becherel, Bahram Bodaghi, Sarah Mrejen-Uretski, Alain-José Sahel, David Saadoun & Marie-Hélène Errera. (2023) The full range of ophthalmological clinical manifestations in systemic lupus erythematosus. Frontiers in Ophthalmology 2.
Crossref
Crossref
Zdeněk Adam, Luděk Pour, Marta Krejčí, David Zeman, Zdeněk Řehák, Renata Koukalová, Viera Sandecká, Martin Štork & Zdeněk Král. (2022) Review of daratumumab efficacy in all monoclonal gammopathies and other diseases and our experience with daratumumab, lenalidomide and dexamethasone therapy in 74 patients. Onkologie 16:Suppl. B, pages 61-82.
Crossref
Crossref
Yaxin Jiang, Jian Sun & Jing Wei. (2022) Distinct binding mode of BAFF antagonist antibodies belimumab and tabalumab, analyzed by computer simulation. Journal of Molecular Modeling 28:10.
Crossref
Crossref
Sha Liu, Zhenqi Sang, Lupin Qin, Wan Gong, Luying Zhao, Qiaoyan Zhang & Qiming Zhao. (2022) Application progress of immobilized biomembrane in the discovery of active compounds of natural products. Biomedical Chromatography 36:10.
Crossref
Crossref
Yu Rebecca Miao, Kaushik Thakkar, Can Cenik, Dadi Jiang, Kazue Mizuno, Chenjun Jia, Caiyun Grace Li, Hongjuan Zhao, Anh Diep, Yu Xu, Xin Eric Zhang, Teddy Tat Chi Yang, Michaela Liedtke, Parveen Abidi, Wing-sze Leung, Albert C. Koong & Amato J. Giaccia. (2022) Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma. Journal of Experimental Medicine 219:9.
Crossref
Crossref
Shumin Zhang, Xiao Han, Wenping Liu, Qiong Wen & Jibo Wang. (2022) Pregnancy in patients with systemic lupus erythematosus: a systematic review. Archives of Gynecology and Obstetrics 308:1, pages 63-71.
Crossref
Crossref
Yoko Hirano, Hideyuki Kosumi, Hajime Miyazawa, Teruki Yanagi, Takahiro Hase, Ayame Kimura, Makoto Saito, Takeshi Kondo & Hideyuki Ujiie. (2021) Toxic epidermal necrolysis induced by tirabrutinib. The Journal of Dermatology 49:4.
Crossref
Crossref
Sining Zhu, Jaeyong Jung, Eton Victor, Johann Arceo, Samantha Gokhale & Ping Xie. (2021) Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies. Frontiers in Oncology 11.
Crossref
Crossref
Donald C. Vinh, Laurent Abel, Paul Bastard, Matthew P. Cheng, Antonio Condino-Neto, Peter K. Gregersen, Filomeen Haerynck, Maria-Pia Cicalese, David Hagin, Pere Soler-Palacín, Anna M. Planas, Aurora Pujol, Luigi D. Notarangelo, Qian Zhang, Helen C. Su, Jean-Laurent Casanova, Isabelle Meyts, Alessandro Aiuti, Lisa M. Arkin, Alexandre Bolze, Samya Charkravorty, John Christodoulou, Roger Colobran, Beth A. Drolet, Jacques Fellay, Pr Antoine Froidure, Jean William Pape, Rabih Halwani, Trine H. Mogensen, Giuseppe Novelli, Igor B. Resnick, Anna Sediva, Ivan Tancevski & Stuart Turvey. (2021) Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β. Journal of Clinical Immunology 41:7, pages 1425-1442.
Crossref
Crossref
Fengping Wu, Jinfang Gao, Jie Kang, Xuexue Wang, Qing Niu, Jiaxi Liu & Liyun Zhang. (2021) B Cells in Rheumatoid Arthritis：Pathogenic Mechanisms and Treatment Prospects. Frontiers in Immunology 12.
Crossref
Crossref
Audrey M. Hagiwara, Richard E. Moore, Daniel J. Wallace, Mariko Ishimori & Caroline A. Jefferies. (2021) Regulation of cGAS-STING pathway - Implications for systemic lupus erythematosus. Rheumatology and Immunology Research 2:3, pages 173-184.
Crossref
Crossref
Sohita Dhillon. (2021) Telitacicept: First Approval. Drugs 81:14, pages 1671-1675.
Crossref
Crossref
Ewa Bryl. (2021) B cells as target for immunotherapy in rheumatic diseases – current status. Immunology Letters 236, pages 12-19.
Crossref
Crossref
Daniel E. Pleguezuelo, Raquel Díaz-Simón, Oscar Cabrera-Marante, Antonio Lalueza, Estela Paz-Artal, Carlos Lumbreras & Antonio Serrano Hernández. (2021) Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome. Frontiers in Immunology 12.
Crossref
Crossref